Levosimendan improves the initial outcome of cardiopulmonary resuscitation in a swine model of cardiac arrest

Acta Anaesthesiol Scand. 2007 Sep;51(8):1123-9. doi: 10.1111/j.1399-6576.2007.01383.x.

Abstract

Background: Cardiac arrest remains the leading cause of death in Western societies. Advanced Life Support guidelines propose epinephrine (adrenaline) for its treatment. The aim of this study was to assess whether a calcium sensitizer agent, such as levosimendan, administered in combination with epinephrine during cardiopulmonary resuscitation, would improve the initial resuscitation success.

Methods: Ventricular fibrillation was induced in 20 Landrace/Large-White piglets, and left untreated for 8 min. Resuscitation was then attempted with precordial compressions, mechanical ventilation and electrical defibrillation. The animals were randomized into two groups (10 animals each): animals in Group A received saline as placebo (10 ml dilution, bolus) + epinephrine (0.02 mg/kg), and animals in Group B received levosimendan (0.012 mg/kg/10 ml dilution, bolus) + epinephrine (0.02 mg/kg) during cardiopulmonary resuscitation. Electrical defibrillation was attempted after 10 min of ventricular fibrillation.

Results: Four animals in Group A showed restoration of spontaneous circulation and 10 in Group B (P = 0.011). The coronary perfusion pressure, saturation of peripheral oxygenation and brain regional oxygen saturation were significantly higher during cardiopulmonary resuscitation in Group B.

Conclusions: A calcium sensitizer agent, when administered during cardiopulmonary resuscitation, significantly improves initial resuscitation success and increases coronary perfusion pressure during cardiopulmonary resuscitation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Agonists / therapeutic use
  • Animals
  • Cardiopulmonary Resuscitation / methods
  • Cardiotonic Agents / therapeutic use*
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Epinephrine / therapeutic use
  • Female
  • Heart Arrest / drug therapy*
  • Hydrazones / therapeutic use*
  • Male
  • Pyridazines / therapeutic use*
  • Random Allocation
  • Simendan
  • Swine
  • Treatment Outcome
  • Ventricular Fibrillation / drug therapy*

Substances

  • Adrenergic alpha-Agonists
  • Cardiotonic Agents
  • Hydrazones
  • Pyridazines
  • Simendan
  • Epinephrine